LeserbriefKommentar
CD7 CAR T-Cell Therapy and Allogeneic HSCT
New England Journal of Medicine · 2024
DOI: 10.1056/nejmc2406366 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Mei Guo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Fifth Medical Center of Chinese PLA General Hospital, Beijing, China guom196801@aliyun.com. Hauptthemen laut MEDLINE: Antigens, CD7, Hematopoietic Stem Cell Transplantation, Immunotherapy, Adoptive. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Antigens, CD7Hematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveHumansCombined Modality TherapyGraft vs Host DiseaseReceptors, Antigen, T-CellReceptors, Chimeric AntigenT-LymphocytesTransplantation, HomologousLeukemiaLymphoma
Substanzen
Antigens, CD7Receptors, Antigen, T-CellReceptors, Chimeric Antigen
Autor:innen und Institutionen
- Fifth Medical Center of Chinese PLA General Hospital, Beijing, China guom196801@aliyun.com.
Zitieren
APA
Guo, M., Yu, C., & Cai, B. (2024). CD7 CAR T-Cell Therapy and Allogeneic HSCT. New England Journal of Medicine. https://doi.org/10.1056/nejmc2406366
Vancouver
Guo M, Yu C, Cai B. CD7 CAR T-Cell Therapy and Allogeneic HSCT. New England Journal of Medicine. 2024. doi:10.1056/nejmc2406366
BibTeX
@article{Guo2024,
author = {Guo, Mei and Yu, Changlin and Cai, Bo},
title = {CD7 CAR T-Cell Therapy and Allogeneic HSCT},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejmc2406366}
}
EUVIMED